How Treatment May Help



In a clinical study called EXIST-3, AFINITOR DISPERZ® (everolimus tablets for oral suspension) was evaluated to determine if it was effective and safe when added to a person's current seizure medicines.


The study showed that when AFINITOR DISPERZ was taken along with other seizure medicines, it helped to reduce how often people had seizures over 12 weeks.


The study had 3 groups of people that received a treatment: placebo (sugar pill), high-dose AFINITOR DISPERZ, and low-dose AFINITOR DISPERZ.


After 12 weeks:

  • 40% of people in the high-dose AFINITOR DISPERZ group had fewer seizures than before treatment with AFINITOR DISPERZ
  • About 29% of people in the low-dose AFINITOR DISPERZ group had fewer seizures
  • About 15% of people in the placebo group had fewer seizures
Percentage of people with fewer seizures

After 12 weeks of taking AFINITOR DISPERZ with other seizure medicines

The study also measured how many people had fewer seizures each week in the placebo and AFINITOR DISPERZ groups.


Average number of seizures per week

Results for the 2 groups treated with AFINITOR DISPERZ were similar, regardless of these 6 characteristics:

Results for the 2 groups treated with AFINITOR DISPERZ were similar, regardless of these 6 characteristics

Hear from world-renowned neurologist Mary Kay Koenig, MD

Dr Koenig explains what causes TSC-associated seizures, why these seizures can be difficult to control, and approaches to managing them, including treatment with AFINITOR DISPERZ. You can also hear about Alee, a patient who experiences TSC-associated seizures, to understand how she and her family have learned to manage these seizures.

Watch Dr Koenig's webcast

See what world-renowned neurologist Mary Koenig, MD, says about how AFINITOR DISPERZ can help reduce the frequency of TSC seizures.